Wladimir Hogenhuis bought $20k of RZLT
director at Rezolute, Inc.. 6,758 shares at an average of $2.92, traded Mar 31, 2025, filed Apr 1, 2025.
Score components
- +15RoleDirector
- 0Trade size$20k at market
- +3Relative to holdingsHoldings up 9%
- +18Price context6% above the 52-week low; 51% below the 52-week high
- +15Cluster3 insiders buying within 14 days
- +5Repeat buying2 buys in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +35.6%, 3m +51.4%, 6m +221.9%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000912282-25-000349, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Mar 31, 2025 | POpen-market purchase Common Shares | +6,758 | $2.92 | $20k | 84,025 | Apr 1, 2025 |
Related signals
Other insiders at Rezolute, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 35Weak | RZLTbuy Rezolute, Inc. | Daron Evans CFO | $29k 10,000 shares | +2% | |
| 38Weak | Rezolute, Inc. | Wladimir Hogenhuis director | $9,549 5,650 shares | +5% | |
| 48Moderate | Rezolute, Inc. | Brian Kenneth Roberts Chief Medical Officer | $48k 28,000 shares | +10% | |
| 58Moderate | Rezolute, Inc. | Nevan C Elam CEO | $51k 32,000 shares | +5% | |
| 62Notable | Rezolute, Inc. | Daron Evans CFO | $80k 45,000 shares | +12% | |
| 44Moderate | Rezolute, Inc. | Sunil Ratilal Karnawat Chief Commercial Officer | $20k 12,100 shares | +20% | |
| 37Weak | Rezolute, Inc. | Brian Kenneth Roberts Chief Medical Officer | $11k 2,500 shares | +19% | |
| 46Moderate | Rezolute, Inc. | Daron Evans CFO | $20k 5,000 shares | +2% | |
| 37Weak | Rezolute, Inc. | Nerissa Kreher director | $9,997 3,076 shares | +9% | |
| 62Notable | Rezolute, Inc. | Young-Jin Kim director | $4.0M 1,230,769 shares | +17% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.